Shattuck Labs (STTK) Cash from Investing Activities (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Cash from Investing Activities of $23.8 million for Q1 2026, up 52.87% year-over-year from $15.6 million in Q1 2025, and up 19.24% quarter-over-quarter from $20.0 million in Q4 2025.
Analysis
Shattuck Labs (STTK) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Cash from Investing Activities for 8 consecutive years, with $23.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 52.87% year-over-year to $23.8 million; the TTM figure through Mar 2026 stood at $361000.0 (down 99.11% YoY), while the FY2025 annual figure was -$7.9 million, up 7.33% from the prior year.
- Cash from Investing Activities advanced to $23.8 million in Q1 2026 per STTK's latest filing, from $20.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $55.9 million in Q4 2023 and bottomed at -$43.5 million in Q3 2025.
- Historically, Cash from Investing Activities has averaged $10.5 million across 5 years, with a median of $17.8 million in 2025.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 611.71% — and 2025, when it plunged 5196.83%.
- Shattuck Labs' Cash from Investing Activities stood at $31.5 million in 2022, then soared by 77.52% to $55.9 million in 2023, then plunged by 44.5% to $31.0 million in 2024, then slumped by 35.48% to $20.0 million in 2025, then gained by 19.24% to $23.8 million in 2026.
- Business Quant data shows STTK's Cash from Investing Activities at $23.8 million in Q1 2026, $20.0 million in Q4 2025, and -$43.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Shattuck Labs | 885.09 Mn | 885.09 Mn | - | -144.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -144.95 Mn |
| Mar 31, 2026 | 23.85 Mn |
| Dec 31, 2025 | 20.00 Mn |
| Sep 30, 2025 | -43.49 Mn |
| Mar 31, 2025 | 15.60 Mn |
| Dec 31, 2024 | 31.00 Mn |
| Sep 30, 2024 | -821,000.00 |
| Jun 30, 2024 | -5.41 Mn |
| Mar 31, 2024 | -33.28 Mn |
| Dec 31, 2023 | 55.85 Mn |
| Sep 30, 2023 | -14.55 Mn |
| Jun 30, 2023 | 24.43 Mn |
| Mar 31, 2023 | 45.13 Mn |
| Dec 31, 2022 | 31.46 Mn |
| Sep 30, 2022 | 29.93 Mn |
| Jun 30, 2022 | 3.43 Mn |
| Mar 31, 2022 | -15.38 Mn |
| Dec 31, 2021 | 25.60 Mn |
| Sep 30, 2021 | 11.24 Mn |
| Jun 30, 2021 | 14.84 Mn |